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Bovine placental lactogen (bPL) is a hormone produced by the fetal portion of the 
placenta during gestation. Although there is little known about the structure and function 
of the protein, it is thought to play a role in the growth of the fetus and in mammary 
growth and differentiation. Attempts have been made to heighten the understanding of 
bPL through the use of recombinant DNA technology. Thus far, researchers have been 
able to produce the recombinant molecule in bacteria cells. Bacteria, however, are 
incapable of carrying out some of the post-translational modifications characteristic of 
mammalian proteins. For example, unlike native bPL, recombinant bPL is non-
glycosylated. Other examples of post-translational modifications include disulfide bond 
formation and correct folding of the protein. The aim of this study, therefore, was to 
clone the bPL cDNA into a mammalian expression vector, amplify the recombinant 
molecule in E. coli cells, and transfect the rbPL into mouse fibroblast cells. The idea 
behind this research was that the mouse cells would be able to produce the bPL complete 
with the post-tanslational modifications seen in the native protein. 
The bPL cDNA was successfully cloned into the pcDNA3.1(+) vector and the 
recombinant molecule was transformed into E. coli cells. The bPL sequence isolated in 
this study was similar to that isolated by Schuler et al. (1988), who were able to divide 
the gene into five exons. The bPL gene in this study was missing the third exon, which 
contains a cysteine residue that is likely involved in the proper folding of the mature 
protein. 
Attempts were made to transfect the pcDNA3.1-bPL into mouse L929 cells. Media 
was collected post-transfection and assayed (Wallace, 1993) for the presence of bPL. An 
average concentration of 1 ng/mL bPL was measured. It was also noted that the 
transfected cells, as compared to control non-transfected cells, grew at a slower rate. 
Initially, it was suspected that the L929 cells were infected with mycoplasma. 
Transfection of a new batch of mouse cells showed improved growth rate, but did not 
produce a higher transfection efficiency. Studies with ovine placental lactogen have 
shown that the 5' flanking sequence of the PL gene is important in the production of the 
protein. In this study, the 5' flanking region of the bPL gene was removed during the 
making of the recombinant bPL molecule. It is therefore hypothesized that the 5' 
flanking sequence of the bPL gene is important to the production of the protein due to the 
low transfection efficiency observed. 
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Chapter 1 
LITERATURE REVIEW 
Introduction 
During pregnancy, a modification in the dam's endocrine production is responsible for 
keeping her offspring alive. Hormones secreted in this crucial period work to maintain 
the fetus and assist the dam in preparing for lactation (Senger, 1999). In 1905, Halban 
was the first to suggest that the hormonal changes noted during gestation could be 
attributed to the newly formed placenta instead of to some preexisting organ. Since then, 
a hormone referred to as placental lactogen (PL) has been identified in primates (Kaplan 
and Grumbach, 1964; Vinik et al, 1973; Blank et al, 1977), rodents (Blank et al, 1977), 
and ruminants (Martal and Djiane, 1975; Chan et al, 1976; Hurley et al, 1977; Becka el 
al, 1977; Currie ef al, 1990). 
The focus of this study is on bovine placental lactogen (bPL). bPL has proven to be 
quite difficult to study since such low levels are found in the circulation of the cow 
during pregnancy (Byatt et al, 1992b). The hormone has been purified from both 
placental homogenates (Murthy et al, 1982) and secretory vesicles (Byatt et al, 1986), a 
grueling process that produces relatively low yields. The aim of this research, therefore, 
is to produce bovine placental lactogen in the laboratory by means of genetic cloning 
techniques, so that we may gain a better understanding of the structure and function of 
the hormone. 
1 
Biosynthesis of bPL 
The placenta is a temporary endocrine organ whose purpose is to mediate metabolic 
exchange between the mother and fetus during pregnancy (Anthony et al, 1995). 
Surrounding the placenta is a layer of cells known as trophoblast cells, approximately 
twenty percent of which are binucleated (Schlafer et al, 2000). These binucleated cells 
appear between days eighteen and twenty in the cow and are formed continuously 
throughout gestation (Senger, 1999). Biosynthesis of placental lactogen, along with other 
pregnancy maintenance hormones and growth factors, takes place within these cells. 
After production, the hormone is stored in the cells' membrane-bound secretory granules 
(Verstegen et al, 1985; Duello et al, 1986; Rice and Thorburn, 1986). It is not until day 
thirty-six that placental lactogen is detectable in the trophoblastic tissue (Buttle and 
Forsyth, 1976), and synthesis of the hormone continues throughout the duration of 
pregnancy. 
Binucleate trophoblast cells are characterized by their ability to migrate into the 
maternal epithelium (Wooding and Wathes, 1980). It was hypothesized that they do so in 
order to transfer a large, non-diffusible molecule across the fetal-maternal microvillar 
junction to the maternal circulation. The possible stages involved in binucleate cell 
migration are diagrammed in Figure 1.1. The fetal binucleate cells are formed in the 
chorion, where they synthesize the granules needed for storing the placental lactogen. 
The cells move toward and make contact with the basement membrane of the uterine 
epithelium, crossing the microvillar junction en route. The granules remain in the fetal 
portion of the cell until the majority of the cell has made its way into the uterine 
epithelium (Wooding and Wathes, 1980). A hybrid cell is formed from the fusion of the 
2 
Maternal capillary 
Fetal capillary 
Figure 1.1. Possible stages involved in binucleate cell migration. (1) A fetal binucleate 
cell is formed in the chorionic epithelium and synthesizes the granules needed for storage 
of the placental lactogen. (2) The cell makes contact with the microvillar junction. (3) It 
crosses the microvillar junction and approaches the basement membrane of the uterine 
epithelium. The granules remain in the fetal portion of the binucleate cell. (4) The 
uterine epithelium contains the majority of the cell. The granules are now scattered 
throughout the entire cell or are localized in the maternal end of the cell. (5) The 
granules have been released into the maternal circulation. The binucleate cell appears to 
have reduced cytoplasm and shrunken, dense nuclei. (6) The binucleate cell is eventually 
taken up by a chorion epithelial cell vacuole. Diagram adapted from Wooding and 
Wathes(1980). 
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binucleate trophoblast cell with the maternal cell. This hybrid cell is referred to as a 
trinucleate "giant" cell (Wooding and Beckers, 1987). Once the two cells fuse, the 
granules containing the placental lactogen are released, thus allowing the entrance of the 
placental lactogen into the maternal circulation. Wooding found no evidence of 
degranulation before migration (Wooding, 1987; Wooding and Beckers, 1987). After 
the granules are released, the binucleate cells appear to have reduced cytoplasm and 
shrunken, dense nuclei. These cells are eventually taken up by the chorion epithelial cell 
vacuoles (Wooding and Wathes, 1980). 
Structure of bPL 
Ruminant placental lactogens are members of the growth hormone(GH)/prolactin 
(PRL) gene family. Despite their many similarities, there is a 10,000 molecular weight 
difference between bPL and the placental lactogens found within sheep and goats, oPL 
and cPL respectively. Ovine and caprine placental lactogens are single-chain 
polypeptides with molecular weights of 21,000 to 23,000 and intramolecular disulfide 
bonds (Chatterjee and Munro, 1977). In contrast, bPL exhibits a complex glycosylation 
pattern (Shimomura and Bremel, 1988; Byatt et al, 1990), a factor that increases its 
molecular weight to 31,000 to 33,000 (Beckers et al, 1980; Murthy et al, 1982; Arima 
and Bremel, 1983). The amino acid composition of the placental lactogens as a whole 
resembles that of GH and pituitary PRL (Chatterjee and Munro, 1977; Hurley et al, 
1977, Vinik et al, 1973). More specifically, the gene for bPL has been determined to 
translate into a 200 amino acid protein that is 50 and 22% similar to bPRL and bovine 
somatotropin (bST), respectively (Schuler et al, 1988). 
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bPL Levels Across Gestation 
Placental lactogen is found in both the fetal and maternal circulations during 
pregnancy. Among the ruminants, cows display the lowest levels of PL. In fact, the 
maternal concentration of PL is 100 to 1000 times greater in sheep and goats than in cows 
(Byatt et al., 1992b). In the cow, fetal serum concentrations of bPL decline throughout 
gestation (Holland et al, 1997), while maternal concentrations peak at day 215 and 
remain high until just prior to birth. The highest reported concentration detected in the 
maternal serum of the cow was 2.93ng/mL (Wallace, 1993). 
Receptor Binding and Biological Activity 
In keeping the structural similarity of bPL to bST and bPRL in mind, it seems to 
follow suit that bPL would bind with high affinity to both bST and bPRL receptors. This 
has, in fact, proven to be the case (Staten et al, 1993; Scott et al, 1992; Gertler et al, 
1996). Growth hormone and PRL receptors belong to the cytokine receptor superfamily. 
A characteristic of this family of receptors is the need for receptor subunit 
homodimerization to initiate signal transduction and ensuing biological activity (Ihle et 
al, 1994). bPL, however, does not appear to have the ability to dimerize these receptors 
(Staten et al, 1993). This seems to suggest that homodimerization is not essential for 
some biological responses signaled through these receptors, since bPL displays both 
somatogenic and lactogenic activity. In fact, recombinant bPL (rbPL) has been shown to 
stimulate weight gain in mature female rats (Byatt et al, 1991) and mammary 
differentiation in steroid-primed dairy heifers (Byatt et al, 1994). 
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In 1995, Anthony et al. suggested several possibilities about the identity of the 
ruminant placental lactogen receptor using the growth hormone receptor as a model 
(Figure 1.2). Ruminant PLs may act by binding to one monomer of the growth hormone 
receptor (GHR), to one monomer of the GHR and an undefined monomer, to two 
monomers of a variant form of the GHR, or to a receptor that is specific for PL. There 
have also been specific binding sites for bPL identified in the bovine endometrium 
(Galosy et al, 1991) and corpus luteum (Lucy et al, 1994), suggesting that bPL plays a 
role in the maintenance of pregnancy. 
Figure 1.2. Possible identity of the ruminant placental lactogen receptor. Ruminant PLs 
may bind to: (a) one monomer of the growth hormone receptor (GHR), (b) one monomer 
of the GHR and an undefined monomer, (c) two monomers of a variant form of the GHR, 
or (d) a receptor that is specific for PL. Diagram adapted from Anthony et al. {1995). 
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Recombinant bPL 
Recombinant analogues of bPL (rbPL), along with GH, PRL, and a few soluble 
extracellular domains of their receptors, have enabled researchers to study the structures 
of the hormones and their interactions with their receptors (Gertler, 1997). To date, rbPL 
has been produced in bacteria cells. Unlike the native protein, rbPL has not been 
glycosylated because bacteria cells are unable to carry out many of the post-translational 
modifications that are common in mammalian proteins. Other examples of post-
translational modifications include the formation of disulfide bonds, proper folding of the 
protein, and addition of carbohydrate chains. 
Disulfide bonds occur between the sulfhydryl groups (-SH) in two cysteine residues of 
a protein (Figure 1.3). 
cysteine 
H | H 1 
+H3N —C—COO" | 
1 + H 3 N - C - C O O " 
i 
CH2 1_ 
1 CH2 
i 
r^  
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S 
I Q CH2 CH2 | 1 
+H3N-C—COO" 
• 
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1 
1 
H 
H 
cysteine 
Figure 1.3. Disulfide bond formation. Disulfide bonds are formed between the 
sulfhydryl groups (-SH) of two cysteine residues. 
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The formation of disulfide bonds is important to the three-dimensional folding of a 
protein (http://www.biotech.vt.edu/classes/bion_4784/4-
GeneExpression/Expression.htmL). Schuler et al. (1988) reported six cysteine residues 
in their bPL sequence assumed to form three disulfide bonds similar to those found in 
bovine PRL. The intracellular reducing environment of E. coli is not conducive to the 
formation of disulfide bonds. In order for disulfide bonds to be formed, it is necessary 
for the protein to be transported to the periplasm of the bacteria. This move needs to be 
directed by the protein itself, by means of a specific signal sequence in the primary amino 
acid sequence (http://www.biotech.vt.edu/classes/bion_4784/4-
GeneExpression/Expression.htmL). 
The proper folding of a protein is accomplished with the help of special proteins 
called chaperones. The correct chaperones needed for the folding of mammalian proteins 
may not be present within the bacteria cells. The incorrect folding results in the 
formation of insoluble aggregates called inclusion bodies 
(http://www.biotech.vt.edu/classes/bion_4784/4-GeneExpression/Expression.htmL). 
Helman et al. (1998) found that after transformation of their recombinant bPL molecule 
into E. coli cells, over 95% of the protein was found in inclusion bodies. A process has 
been established to make the protein in inclusion bodies soluble and to refold it, but this 
is a process that often fails (http://www.biotech.vt.edu/classes/bion_4784/4-
GeneExpression/Expression.htmL). 
A characteristic of bPL is that it is glycosylated, meaning that it has carbohydrate 
groups attached at specific amino acid sequences (Shimomura and Bremel, 1988; Byatt et 
al., 1990). Bacteria are not able to add these carbohydrate groups. Studies have shown 
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that enzymatic removal of the N-linked oligosaccharides of bPL causes increased binding 
to growth hormone receptors (Byatt et at, 1990). rbPL is therefore active, despite the 
fact that it is not glycosylated, but it does not resemble the native protein as closely as it 
could. 
The key to producing bPL that is as close to the native protein as possible is to 
produce it in mammalian cells. The mammalian endoplasmic reticulum is a more 
suitable environment for disulfide bond formation. In addition, mammalian cells possess 
the appropriate chaperones needed for the proper folding of a mammalian protein, and 
they are able to add carbohydrates in the correct locations 
(http://www.biotech.vt.edu/classes/bion_4784/4-GeneExpression/Expression.htmL). The 
aim of this study, therefore, is to clone the bPL cDNA into a mammalian expression 
vector and amplify the recombinant molecule in E. coli cells. The final step will be to 
transfect the rbPL into mouse cells with the hopes that the mouse cells will be able to 
express the hormone complete with the post-translational modifications that are 
characteristic of native bPL. The following sections introduce the gene cloning 
techniques that will be used to accomplish such a feat. 
Gene Cloning 
The birth of genetics dates back over a century ago beginning with Gregor Mendel, 
who devised a set of rules explaining that inherited traits were controlled by factors called 
genes. Next came the discovery of chromosomes by Sutton in 1903 and the development 
of techniques for gene mapping by Morgan and his associates in the early 1920s. It was 
not, however, until the work of Avery, MacLeod and McCarty in 1944, and of Hershey 
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and Chase in 1952, that DNA was identified as the genetic material. Between the years 
1952 and 1966 scientists began to understand the structure of DNA, the genetic code, and 
the processes of transcription and translation. Finally, in the years 1971-1973 came the 
advent of recombinant DNA technology, otherwise known as genetic engineering, the 
basis of gene cloning. Gene cloning involves the insertion of a fragment of DNA 
carrying a gene into a cloning vector. The cloning vector will then facilitate the entry of 
the recombinant molecule into a host organism, where the gene can be amplified. The 
next sections will explain the methods involved in the amplification of a gene and the 
subsequent in vitro production of the protein that it codes for (Brown, 1995). 
Reverse Transcription-Polymerase Chain Reaction (RT-PCR) 
Often times, RNA is isolated from a tissue and used as the starting material for genetic 
engineering studies. The cells of that tissue contain the DNA sequence needed to make 
up the whole organism, but actually express relatively few of the genes. Only those 
genes that are being expressed are transcribed into messenger RNA (mRNA). Extracting 
the RNA therefore ensures that the researcher is working with only those genes that are 
expressed in the tissue of interest (Brown, 1995). 
mRNA cannot be ligated into a cloning vector, so it is necessary to convert it into 
DNA by complementary DNA (cDNA) synthesis. This is achieved through the process 
known as reverse transcription (RT) in which the enzyme reverse transcriptase is used to 
synthesize a DNA strand complementary to an existing RNA strand. The RNA strand is 
then degraded, leaving a single-stranded cDNA. It is then possible to proceed with the 
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ploymerase chain reaction (PCR), thus amplifying the actual gene of interest (Brown, 
1995). 
The first step of the PCR is primer design. Primers are generally 17 to 30 base pair 
oligonucleotides that correspond to the regions flanking the gene of interest. A primer 
that is too short may be able to anneal to a site other than the site directly before the gene, 
while a primer that is too long will hybridize at a slower rate, reducing the efficiency of 
the PCR. One PCR cycle is composed of three steps: (1) denaturation of the double-
stranded DNA, (2) hybridization of the primers to the templates, and (3) DNA synthesis. 
The cycle is usually repeated 25-30 times, resulting in the production of several hundred 
million copies of the gene (Brown, 1995). 
Each step of the PCR is carried out at a particular temperature. Denaturation of the 
double-stranded DNA usually takes place at 94°C. At this temperature, the base pairs are 
broken releasing single-stranded DNA that can act as templates. The temperature at 
which the primers hybridize or anneal to the templates is dependent upon the length and 
sequence of the primers themselves. By determining the melting temperature (Tm) of the 
primer template hybrid, it is possible to estimate the temperature at which a hybrid would 
form. For a primer of 21 base pairs or less the Tm would be calculated as follows: 
Tm = (4 x [G + C]) + (2 x [A + T]) °C 
in which [G + C] is the number of guanine (G) and cytosine (C) nucleotides in the primer 
sequence and [A + T] is the number of adenine (A) and tyrosine (T) nucleotides in the 
primer sequence. For a primer that is more than 21 nucleotides in length, the Tm is 
calculated as follows: 
Tm = 69.3 + (0.41 x [G + C]%) - (650/primer length) 
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Where [G + C]% is the percentage of the primer that is made up of either G or C 
nucleotides and the primer length is the total number of nucleotides comprising the 
primer. The hybridization temperature is usually 1-2°C lower that the calculated Tm. 
DNA synthesis usually occurs at 74°C, which is just below the optimum temperature for 
Taq polymerase, the enxyme used to facilitate the production of the complementary 
strands. Taq polymerase is an ideal enzyme to use because, unlike most DNA 
polymerases, it can withstand the high temperatures used during the PCR. Figure 1.2 is a 
diagrammatic representation of a RT-PCR (Brown, 1995). 
Ligation and Transformation 
The DNA fragments resulting from the RT-PCR can now be ligated into a vector to 
produce a recombinant DNA molecule. The vector acts as a vehicle to transport the DNA 
fragment into a host bacterium. The introduction of the DNA into the living cell is 
referred to as transformation. Once inside the host cell, the vector multiplies, 
manufacturing numerous copies both of itself and of the DNA fragment that it carries. 
Copies of the recombinant molecule are passed on to the progeny of the host cell, where 
the vector and the DNA fragment can be replicated further. Eventually, a colony of host 
cells is produced, with each cell containing at least one copy of the recombinant 
molecule. It is then that the DNA fragment carried by the vector is said to be cloned 
(Brown, 1995). 
There are two kinds of vectors that are used in gene cloning: plasmids and 
bacteriophages. This study will concentrate on plasmids, circular molecules of DNA that 
act independently within the bacterial cell. Plasmids often times carry special genes, for 
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example, genes that confer antibiotic resistance. Bacteria itself cannot grow in the 
presence of antibiotics. However, if the plasmid that it carries has an ampicillin 
resistance gene, the bacteria will be able to display resistance to that particular antibiotic. 
Therefore, culturing in growth media containing ampicillin would ensure that the 
colonies that grow contain the plasmid. Another characteristic of plasmids is that they 
have at least one DNA sequence that can act as an origin of replication. This allows the 
plasmid to multiply within the host independently of the host's chromosome (Brown, 
1995). 
Transfection 
One problem with using bacteria as hosts for recombinant protein synthesis is that the 
bacteria may not process the recombinant protein correctly. Mammalian proteins are 
processed after translation by means of chemical modification of the amino acids. The 
post-translational modifications, glycosylation for example, which take place are often 
essential for the correct biological activity of the protein. Certain post-translational 
modifications such as glycosylation are extremely uncommon in bacteria, therefore the 
bacterial cells are unable to glycosylate the recombinant protein correclty. Transfecting 
the recombinant DNA molecule into mammalian host cells is a way to circumvent this 
problem. 
Transfection is defined as the process of introducing nucleic acids into cells by non-
viral methods. This can be achieved through both chemical and physical means. DEAE-
dextran, calcium phosphate, and artificial liposomes are examples of chemical reagents 
often used to facilitate the transfer of nucleic acids into cultured mammalian cells. 
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Physical methods include direct microinjection (Cappechi, 1980), electroporation (Wong 
and Neumann, 1982), and biolostic particle delivery (Ye et al, 1990). This study will 
focus on the use of artificial liposomes. 
Tfx Reagents (Promega), the transfection reagents used in this study, employ cationic 
lipids in the delivery of nucleic acids to eukaryotic cells. They are a mixture of the 
synthetic cationic lipid molecule N,N,N',N'-tetramethyl-N,N'-bis(2-hydroxyethyl)-2,3-
di(oleoloxy)-l,4-butanediammonium iodide and the neutral lipid L-dioleoyl 
phosphatidylethanolamine (DOPE). The structures of these compounds are shown in 
Figure 1.4. Presumably, the cationic portion of the lipid molecule associates with the 
negatively charged nucleic acid that is to be transferred into the mammalian cell (Figure 
1.5). This creates a lipid/nucleic acid complex with an overall net positive charge. The 
complex is then able to closely associate with the negatively charged cell membrane and 
is endocytosed by the cell. It has been suggested that DOPE works to release the 
complexes from the endosomes so that they may make their way into the nucleus 
(Farhood et al, 1995). 
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(a) 
Figure 1.4. Components of the Tfx transfection reagents. The Tfx reagents (Promega) are 
a mixture of (a) the synthetic cationic lipid molecule N,N,N',N'-tetramethyl-N,N,-bis(2-
hydroxyethyl)-2,3-di(oleoloxy)-l,4-butanediammonium iodide and (b) the neutral lipid 
L-dioleoyl phosphatidylethanolamine (DOPE). 
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Figure 1.5. Schematic representation of a lipid/nucleic acid complex. The cationic 
portion of the lipid molecule associates with the negatively charged nucleic acid. This 
creates a lipid/nucleic acid complex with an overall net positive charge. The complex is 
then able to closely associate with the negatively charged cell membrane and is 
endocytosed by the cell. 
16 
Chapter 2 
MATERIALS AND METHODS 
RNA Extraction and Reverse Transcription-Polymerase Chain Reaction 
Placental tissue was obtained from a Holstein dairy cow that was at day 90 of 
gestation at the time of slaughter. The tissue was divided into two 1.5mL eppendorf 
tubes, one containing a mass of 140mg and the other 150mg. The two samples were 
maintained at -70°C until the time of their use. The initial steps of the bPL cloning 
process, the RNA extraction and the reverse transcription-polymerase chain reaction (RT-
PCR), were performed by Michael Jordan, an undergraduate working on his senior 
project under the supervision of Dr. Eric Anderson, PhD. 
The RNA was extracted from the samples of placental tissue using the Trizol LS 
Reagent protocol from GibcoBRL. The Trizol LS Reagent isolates total RNA from 
liquid samples taken from humans, animals, plants, yeast, bacteria, and viruses. As the 
samples were being homogenized, the Trizol LS Reagent disrupted the cellular 
components, while at the same time keeping the RNA intact. The solution was next 
separated into an aqueous phase (containing the RNA) and an organic phase by the 
addition of chloroform followed by centrifugation. Once the aqueous phase was 
collected, isopropyl alcohol was added to it to precipitate the RNA. The resulting pellet 
was washed with 75% ethanol, allowed to dry, and dissolved in 20mL RNase-free H20. 
The tubes containing the RNA were stored at -20°C. 
Oligonucleotide primers were designed using a known bPL sequence obtained from 
GenBank, accession number M33268. This sequence, reported by Yamakawa el al. 
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(1990) is detailed in Figure 2.1. Also included in Figure 2.1 are the positions of the 
primer sequences, labeled bPL-F (forward) and bPL-R (reverse). The bPL-F primer (5' 
CCT CCA TTC AGT CCC TGT TGG 3') was a 21-mer with a melting temperature (Tm) 
of 66°C, while the bPL-R primer (5' GAG ACC CAT TAC ACC CAA AC A TG 3') was 
a 23-mer with a Tm of 60.6°C. Both primers were obtained from Sigma. 
Reverse transcription (RT) was performed on both of the sample tubes containing the 
extracted RNA. The reactions were set up as shown in Table 2.1. 
Table 2.1. Reverse transcription reactions 
Tube RNA template bPL-R RNAse out H2Q Total volume 
1 2ul from 140mg sample lul lul 6ul lOul 
2 2JJ.1 from 150mg sample lul lul 6ul lOul 
_3 °_ It! IH] M lOul 
The reverse transcription reactions were produced by mixing the RNA template, the bPL-
R (reverse) primer (Sigma), RNAse out, which destroys RNAses (Sigma), and distilled 
water. 
Each reaction was incubated at 72°C for two minutes, allowing the primer to anneal to 
the template. The RT reaction cocktail (Table 2.2) was then prepared. Reverse 
transcription reaction cocktail (Table 2.2) was added to each of the three reaction tubes at 
a volume of 5.8ul per tube. The tubes were then incubated at room temperature for 10 
minutes, followed by an incubation of 1 hour at 42°C. The resulting products served as 
the templates for the polymerase chain reactions (PCR). 
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bPL-F 
5| gcact tccccaccacagat t tcctccat tcagtccctgt t g g g c c a t c t c c c c a t c c a g c 60 
3' c g t g a a g g g g t g g t g t c t a a a g g a g g t a a g t c a g g g a c a a c c c g g t a g a g g g g t a g g t c g 
a g c a g t c c c t g c a t c c t g g g a t t t c t c t ccaa t cct c|a"Tg|gc t ccagca t ctagcca t eg 120 
t c g t c a g g g a c g t a g g a c c c t a a a g a g a g g t t a g g a g T i c c g a g g t e g t a g a t e g g t a g e 
t g g g c a c c a g t g g a t t t g t g a c c t t g t t c g a g g g t c c t g c c t g c t c c t g c t g c t g g t g g t 180 
a c c c g t g g t c a c c t a a a c a c t g g a a c a a g c t c c c a g g a c g g a c g a g g a c g a c g a c c a c c a 
g t c a a a t c t a c t c t t g t g c c a g g g t g t g g a g g a t t a t g c a c c a t a c t g t a a a a a c c a a c c 240 
c a g t t t a g a t g a g a a c a c g g t c c c a c a c c t c c t a a t a c g t g g t a t g a c a t t t t t g g t t g g 
t g g c a a c t g c c g g a t t c c c c t t c a a a g c c t g t t t g a g a g a g c a a c a t t g g t g g c t a g c a a 300 
a c c g t t g a c g g c c t a a g g g g a a g t t t c g g a c a a a c t c t c t c g t t g t a a c c a c c g a t c g t t 
c a a c t a t a g g c t c g c c a g g g a a a t g t t c a a t g a a t t t a a t a a a c a g t t t g g c g a g g g c a a 360 
g t t g a t a t c c g a g c g g t c c c t t a c a a g t t a c t t a a a t t a t t t g t c a a a c c g c t c c c g t t 
aaact tcact t c c a a g g t c a t c a a c a g c t g c c a c a c c g a a t t c a t g a c t a c c c c t a a t a a 420 
t t tgaagtgaaggt tccagtagt tgtcgacggtgtggct taagtactgatggggat tat t 
c a a a g a a g c a g c t g c a a a t a c a g a g g a c g a a g c c c t g t tgaggt tggt tatcagt t tget 480 
gt t tct t eg t eg a eg tt tatgtctcctgct t c g g g a c a a c t c c a a c c a a t a g t c a a a c g a 
c c a c t c g t g g g a t g a a c c t c t g c a t c a g g c a g t c a c a g a g t tgt t g c a c a g g a a t g g a g c 540 
gg t g a g c a c c c t a c t t g g a g a c g t a g t c c g t c a g t g t c t c a a c a a c g t g t c c t tacctcg 
c t c a c c t g a t a t c t t g g c a a g g g c t a a a g a g a t t g a g g a c a a g a c c a a a g t a c t t c t a g a 600 
g a g t g g a c t a t a g a a c c g t tcccgat t tctctaactcctgt tctggt t tcatgaagatct 
a g g t g t g g a a a t g a t a c a a a a a a g g g t t c a t c c t g g a g a g a a g a a g a a c g a g c c c t a t c c 660 
t c c a c a c c t t t a c t a t g t t t t t t c c c a a g t a g g a c c t c t c t t c t t c t t g c t c g g g a t a g g 
a g t g t g g t c a g a a a a g t c c t c c c t g a c a g c a g a c g a t g a g g a t g t g c g c c a a a c t g c c t t 720 
t c a c a c c a g t c t t t t c a g g a g g g a c t g t c g t c t g c t a c t c c t a c a c g c g g t t t g a c g g a a 
t tatagaatgt tccactgcctacacagggat tcgagtaaaat tagcacctacatcaat 11 780 
a a t a t c t t a c a a g g t g a c g g a t g t g t c c c t a a g c t c a t t t t a a t c g t g g a t g t a g t t a a a 
get taagtgccgat tcacccca tgcjt aajgcccacaa ttaacccaaccagt cct gaga tgg 840 
c g a a t t c a c g g c t a a g t g g g g t a c g a t t c g g g t g t t a a t t g g g t t g g t c a g g a c t c t a c c 
t t a c g t g a t g a t c c a t c c c g t c a a a a g c t t c t t t g a g t t t t a t a g c t c t t t a a t g c a t g t 900 
a a t g c a c t a c t a g g t a g g g c a g t t t t c g a a g a a a c t c a a a a t a t c g a g a a a t tacgtaca 
t t g g g t g t a a t g g g t c t c a t c t g a a a c a a a a t a a a c a c a g a t t c t g t a g a g a t g t c a a a a 960 
a a c c c a c a t t a c c c a g a g t a g a c t t t g t t t t a t t t g t g t c t a a g a c a t c t c t a c a g t t t t 
bPL-R 
atct_ 3' 965 
tagaa 5' 
Figure 2.1. bPL sequence obtained from GenBank, accession number M33268. 
This sequence originally appeared in a paper written by Yamakawa et al. (1990). The 
initiation codon (ATG) and stop codon (TAA) are identified with boxes around them. 
The primer sequences (bPL-F and bPL-R) are underlined. 
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Table 2.2. Preparation of the reverse transcription reaction cocktail. 
Component Volume per reaction tube 
5x RT buffer 3uJ 
0.1MDTT lul 
lOmMdNTP lul 
Superscript Q,8ul  
Total volume 5.8ul  
Three clean microfuge tubes were obtained and 47.5 ul of the PCR cocktail (Table 
2.3) was added to each. Next, 2ul of each template was added to its respective tube. The 
control tube (tube 3) received 2ul RNase-free H2O. Taq polymerase was added at a 
volume of 0.5ul per reaction tube. The polymerase chain reactions were performed in the 
PTC-100 Programmable Thermal Controller (M.J. Research). 
Table 2.3. Preparation of the polymerase chain reaction cocktail. 
Component Volume per reaction tube 
H20 27.5ul 
MgCl2 5ul 
1 Ox buffer 5ul 
2mM dNTP 5ul 
bPL-F 2.5ul 
bPL-R 2.5ul 
Total volume 47.5ul  
Gel Extraction of the PCR Product 
A sample of each PCR product (from tubes 1 and 2) was run on agarose (1%) gel 
electrophoresis and the bPL DNA fragments were excised using a scalpel. The QIAquick 
Gel Extraction Kit (QIAGEN) was used to extract and purify the DNA from each gel 
slice. The volumes of buffer QG and isopropanol used during the purification process 
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were based on the masses of the excised gel slices. The gel slices were weighed and 3 
volumes of buffer QG were added per one volume of gel. Likewise, one gel volume of 
isopropanol was added at the appropriate time. The volumes used are outlined in Table 
2.4. The optional step 9 was followed and the DNA was eluted with water. 
Table 2.4. Reagent volumes used in the gel extraction of bPL. 
Mass of placental tissue Mass of gel slice Buffer QG Isopropanol 
140mg HOmg 330ul ~~ HOul 
150mg 120mg 360ul 120u1 
The mass of each gel slice was used to determine the volumes of buffer QG and 
isopropanol used in the gel extraction process. 
The purified bPL insert originating from the HOmg sample of placental tissue was used 
in the following ligation step. 
Ligation of bPL with the pTarget Mammalian Expression Vector 
The purified bPL insert was next ligated into the pTarget Mammalian Expression 
Vector (Figure 2.2) from Promega. In order to accomplish this, three ligation reactions 
were set up (Table 2.5). Each reaction was brought to a total volume of lOul with the 
addition of sterile dL^O. The reactions were then kept at 4°C overnight (18 hours), 
resulting in the production of recombinant pTarget-bPL molecules. 
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Table 2.5. Reactions set up for the ligation of the bPL insert into the pTarget vector. 
Components Ligation 1 Ligation 2 Ligation 3 
Vector luj 1^x1 lul 
bPL insert 2.5ul 5ul 7ul 
lOx ligation buffer 1 jn.1 l u l 1 jul 
Sterile dH20 4.5^1 2^1 0 
T4 DNA Ligase ljjj ljol 1^ 1 
The components of the three ligation reactions are listed above. The lOx ligation buffer 
and T4 DNA ligase were provided along with the pTarget vector (Promega). 
Transformation of Recombinant pTarget-bPL into E. coli Cells 
One tenth dilutions of each ligation product were made by adding lul recombinant 
DNA to 9ul sterile dH20. Three eppendorf tubes were placed on ice. A volume of 50ul 
competent JM109 E. coli cells was added to each tube, along with 1 ul of the 
corresponding DNA dilution. The tubes were kept on ice for 30 minutes, placed at 42°C 
for 45 seconds, and then returned to the ice for 2 minutes. At the end of that time, 500uJ 
SOC broth (sterile solution that supplies amino acids and other nutrients) was added to 
each tube. The tubes were then placed in the 37°C shaker (set at 220rpm) for 1 hour. 
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Bgl II 5665 
SgfI 664 
Intron 
pTarget Vector 
(5670 bp) 
Synthetic poly(A) 
Cytomegalovirus immediate early 
enhancer/promoter: bases 1 -750 • 
SV40 enhancer/early promoter: 
bases 2260-2630 
SV40 late polyadenylation signal: 
bases 1535-1755 
Neomycin selectable marker: 
bases 2675-3469 
Phage fl region: bases 1798-2252 I"""! Ampicillin resistance gene: 
L J bases 3978-4838 
Figure 2.2. Map of the pTarget mammalian expression vector. This map is based on the 
map provided by Promega. 
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Plating the Transfbrmants 
The transformants were plated on LB/Amp/IPTG/X-gal plates (lOOug/mL ampicillin, 
0.5mM IPTG, and 80u.g/mL X-gal), with two plates per transformation reaction. The six 
plates were labeled la, lb, 2a, 2b, 3a, and 3b and were allowed to incubate at 37°C 
overnight. Following the incubation period, the plates were stored at 4°C. 
Inoculation of Colonies into LB Broth 
Two white colonies from each plate were chosen for culture. These colonies were 
labeled lal, la2, lbl, lb2, 2al, 2a2, 2bl, 2b2, 3al, 3a2, 3bl, and 3b2. Each clone was 
inoculated into 2mL LB broth containing lOOug/mL ampicillin. The tubes were set in the 
37°C shaker (set at 220rpm) overnight, after which the cultures were immediately 
purified using the QIAspin Mini-prep Kit (QIAGEN). All cultures grew except that 
inoculated with clone pTarget-bPL-2b2. During the purification process, the pelleted 
DNA was reconstituted in sterile dH20. The resulting purified DNA was stored at -20°C. 
Restriction Digests 
Each sample of purified DNA was digested with the restriction enzymes Kpn I and 
BamH I in order to determine if it contained the bPL insert. Digestion with these two 
enzymes would effectively separate the insert from the vector since the BamH I 
recognition site was located 5' of the insert, while the Kpn I recognition site was located 
3' of the insert. Another important reason for using these two enzymes was that there 
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was only one recognition site for each in the entire recombinant molecule. Table 2.6 
gives the components of one digestion reaction and a cocktail recipe for 12 digests. 
Table 2.6. Components of a double digest using Kpn I and BamH I. 
Component Volume per digest 
lOxNEBufferl 2ul 
BSA(lmg/mL) 2ul 
RNAse-free H20 9ul 
Kpn I 1 ui 
BamH I ]jd 
Each digest was carried out in a 0.5mL eppendorf tube. Digest mix was added to each of 
the 11 eppendorf tubes at a volume of \5\il per tube. Next, 5ul purified DNA was added 
to the respective tubes. The digests were incubated at 37° for 2 hours. In order to stop 
the action of the enzymes, 4)j.l loading dye was added to each of the digests. 
Gel Electrophoresis of Digested DNA 
The digests, along with a lOObp ladder from GibcoBRL, were run on a 1% agarose gel 
stained with ethidium bromide. Each of the digests was loaded into the appropriate well 
and the gel was run at 275 V for 15 minutes. Photographs of the gel were taken using the 
Chemilmager 4400 Low Light Imaging System. 
25 
DNA Sequencing 
Each clone appeared to contain the bPL insert, and was therefore sent to the 
University of Maine DNA Sequencing Facility to be sequenced. The sequences returned 
were analyzed using the MegaBLAST program provided by the National Center for 
Biotechnology Information (NCBI). 
Digest of pTarget-bPL-lb2 and pTarget-bPL-3al and Isolation of the bPL Gene 
The results of the MegaBLAST showed that the bPL gene, although present, was in 
the incorrect orientation. This made it necessary to remove the gene from the pTarget 
vector for insertion into another mammalian expression vector, the pcDNA3.1(+) vector 
from Invitrogen (Figure 2.3). Clones pTarget-bPL-lb2 and pTarget-bPL-3al were 
chosen at random to digest. The double digest using the restriction enzymes Kpn I and 
BamH I (Table 2.6) was again employed. The two digests were run on a 1% agarose gel 
stained with ethidium bromide and the bPL DNA fragments were excised and purified 
using the QIAquick Gel Extraction Kit (QIAGEN). 
Digest and Purification of the pcDNA3.1(+) Vector 
The pcDNA3.1 vector was also digested with Kpn I and BamH I. The reaction was 
set up as shown in Table 2.7. 
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Figure 2.3. Map of the pcDNA3.1 mammalian expression vector. This map is based on 
the map provided by Invitrogen. 
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Table 2.7. Restriction digest of the pcDNA3.1(+) vector. 
Component Volume  
lOxNEBufferl 16ul 
BSA(lmg/mL) 16ul 
Sterile dH20 72ul 
Kpn I 8ul 
BamHI 8ul 
Added to the reaction mixture was 40ul pcDNA3.1(+) vector. The digest was incubated 
at 37°C for four hours. Following the incubation period, the digest was set in a 60°C 
water bath to stop the reaction. Purification was achieved through the use of the 
QIAGEN PCR Purification Kit (QIAGEN). 
Ligation of bPL into the pcDNA3.1(+) Vector and Transformation into E. coli 
The protocol used previously to ligate the bPL gene into the pTarget vector (Table 
2.5) was used again to ligate the bPL gene digested from the pTarget-bPL clones into the 
pcDNA3.1 vector. The recombinant molecules were transformed into competent JM109 
E. coli cells and the transformants were plated on LB/Amp plates. The resulting colonies 
were cultured, purified, and digested with Kpn I and BamH I (as described) to confirm 
the presence of the bPL inserts. Samples that appeared to have the insert were sent to the 
University of Maine DNA Sequencing Lab to be sequenced. The sequences obtained 
(Figure 2.4) were analyzed using MegaBLAST. 
Production of Primers bPL-Start-Kpnl and bPL-Stop-BamHI 
According to the pcDNA3.1 product manual, the insert must contain a Kozak 
translation initiation sequence for proper initiation of translation to occur. It is critical to 
have a G or A at position -3 and a G at position +4 (positions are relative to the start 
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codon). The pcDNA3.1-bPL-3a 1-2-1 sequence did have a G at position +4, but had a C 
in place of the required G or A at position - 3 . In order to rectify this, new primers, bPL-
Start-Kpnl and bPL-Stop-BamHI, were designed. Primer bPL-Start-Kpnl (51 
GTTCATGGTACCGCTATGGCTCCAGCATCTAGCC 3') also incorporated a Kpn I 
recognition site (GGTACC) prior to the start codon. Primer bPL-Stop-BamHI (5' 
GTACCTGGATCCTTAGCATGGGGTGAATCGGC 3') incorporated a Bamll I 
recognition site (GGATCC) following the stop codon. The placement of these primers 
can be seen in Figure 2.4. 
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5' ggtacccccgggaaagattcctccattcagtccctgttgggccatctccccatcagcagc 60 
s ccatgggggccctttctaaggaggtaagtcagggacaacccggtagaggggtagtcgtcg 
Kpn I Sma I 
bPL-Start-Kpnl 
gttcatggtaccgct 
agtcctcatcctgggatt t c t c t c c S M cc t c]atg]gctccagca tc tagcca t eg t gggc 120 
tcaggagtaggaccctaaagagaggt taggagtaccgaggtcgtagatcggtagcacccg 
accagtggatttgtgaccttgttcgagggtcctgcctgctcctgctgctggtggtgtcaa 180 
tggtcacctaaacactggaacaagctcccaggacggacgaggacgacgaccaccacagtt 
atctactcttgtgccagggtgtggaggattatgcaccatactgtaaaaaccaacctggca 240 
tagatgagaacacggtcccacacctcctaatacgtggtatgacatttttggttggaccgt 
actgccggattccccttcaaagcctgtttgagagagcaacattggtggctagcaacaact 300 
tgacggcctaaggggaagtttcggacaaactctctcgttgtaaccaccgatcgttgttga 
ataggctcgccagggaaatgttcaatgaatttgacgaagccctattgaggttggttatca 360 
tatccgagcggtccct t tacaagt tact taaactget tcgggataactccaaccaatagt 
gt t tgctccactcgtgggatgaacctctgcatcaggcagtcacagagt tgt tgcacagga 420 
caaacgaggtgagcaccctacttggagacgtagtccgtcagtgtctcaacaacgtgtcct 
atggagcctcacctgatatct tggcaagggctaaagagat tgaggacaagaccaaa;gtac 480 
tacctcggagtggactatagaaccgt tcccgat t tctctaactcctgt tctggt t tcatg 
t tctagaaggtgtggaaatgatacaaaaaagggt tcatcctggagagaagaagaacjiagc 540 
aagatct tccacacct t tactatgt 1111 tcccaagtaggaicctctcttct tct tgeteg 
cctatccagtgtggtcagaaaagtcctccctgacagcagacgatgaggatgtgcgccaaa 600 
ggataggtcacaccagtcttttcaggagggactgtcgtctgctactcctacacgcggttt 
ctgccttttatagaatgttccactgcctacacagggattcgagtaaaattagcacctaca 660 
gaeggaaaatatet tacaaggtgacggatgtgtccctaagctcat 11 taatcgtggatgt 
tcaatttgcttaagtgccgat t cacccca t gcfTTaJgcccacaa t taacccaaccagtcct t'Ai 
agt taaacgaat tcacggctaagtggggtacgaTTcgggtgttaattgggttggtcagga 
cctaggtccatg 
bPL-Stop-BamFil 
gagatggttagtgatgatccatcccgtcaaaagcttctttgagttttatagctctttaat 780 
ctctaccaatcactactaggtagggcagttttcgaagaaactcaaaatatcgagaaatta 
gcatgtttgggtgtaatgggtctcaatcacgegtctcgaggctagcaaggatcc 3' 834 
cgtacaaacccacattacccagagt tagtgcgcagagctccgatcgttcctagg b' 
Mlu I Xho I Nhe I Bam H I 
Figure 2.4. pcDNA3.1-bPL-3al-2-l sequence. The placement of the new primer 
sequences (bPL-Start-Kpnl and bPL-Stop-BamHI) are indicated in bold and underlined. 
The cut sites incorporated into the sequence from the pTarget vector are underlined either 
once or twice 
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PCR 
A PCR was set up using pcDNA3.l-bPL-3a 1-2-1 as the template and bPL-Start-Kpnl 
and bPL-Stop-BamHI as the primers (Table 2.8). 
Table 2.8. PCR using pcDNA3.1-bPL-3al-2-l as the template. 
Component Volume  
PCR buffer 88ul 
Taq polymerase 2ul 
bPL primer pair (5uM each) 4ul 
pcDNA3.1-bPL-3al-2-l 8uJ 
In order to make the bPL primer pair, 1 Oul of each primer (1 OOuM each) was added to 
180ul H2O. The mixture was divided into four PCR tubes (25ul each) and the reaction 
was run for 35 cycles using a 55°C annealing temperature in the PTC-100 Programmable 
Thermal Controller. The PCR product was run on a 1.5% gel stained with ethidium 
bromide at 172V for 13 minutes. The remaining 90ul of PCR product was purified using 
the QIAquick PCR Purification Kit (QIAGEN) and the DNA was eluted with 40u1 buffer 
EB (provided in the purification kit). 
Restriction Digest of the PCR Product 
A double digest using the restriction enzymes Kpn I and BamH I was performed on 
the PCR product (Table 2.9). 
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Table 2.9. Restriction digest of the PCR product using Kpn I and Bam 11 I. 
Component Volume  
PCR product 20u1 
Buffer NEB 1 lOul 
lOOxBSA lul 
Kpn I 4ul 
BamH I 4ul 
Sterile dH2Q 6uJ 
The reaction was incubated at 37°C for 30 minutes. In order to stop the action of the 
enzymes, lOjul 6x dye was added to the PCR product digest. The sample was run on a 
1.5% agarose gel stained with ethidium bromide at 172V for 13 minutes. The band 
corresponding to the estimated size of the insert was excised from the gel and purified 
using the QlAquick Gel Extraction Kit (QIAGEN). The DNA was eluted in 20ul buffer 
EB (provided in the kit). 
Ligation of the bPL Insert into the pcDNA3.1(+) Vector 
A different protocol was used to ligate the new bPL insert into the pcDNA3.1(+) 
vector. This protocol involved a 1:1 ligation of insertvector with 500ng DNA total. 
Table 2.10 shows the reaction components. The mixture was incubated at 15°C 
overnight (16-18 hours). 
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Table 2.10. Ligation of the bPL insert into the pcDNA3.1(+) vector. 
Component Volume 
PCR product " 20ul 
BSA(2mg/mL) lul 
Fresh 4mM ATP 2ul 
Sterile dH20 1 Oja.1 
T4 Ligase 1 p.1 
bPL insert 0.3ul 
Cut pcDNA3.!(+) vector 3.7ul 
Transformation of the Recombinant DNA into Competent E. coli cells 
A different transformation technique was also employed. To a chilled tube was added 
lOOul cold lOOmM Tris HC1 (pH 7.4), 20ul ligation reaction, and 200ul competent 
DH5a E. coli cells. The tube was incubated on ice for 20 minutes, heatshocked for two 
minutes at 42°C, and then allowed to stand at room temperature for 10 minutes. At the 
end of the incubation period, 2mL LB broth was added. The mixture was incubated at 
37°C in the shaker (set at 220rpm) for one hour, followed by centrifugation at 6000xg for 
five minutes. The supernatant was decanted and the pellet resuspended in 200ul LB 
broth. Samples (5ul and 50ul) were plated on LB/Amp plates with the concentration of 
ampicillin at 50ug/mL. Three colonies were chosen for culture in LB broth containing 
lOOug/mL ampicillin. The DNA was purified using the QIAquick Spin Mini-prep Kit 
(QIAGEN) and the purified DNA was digested with Kpn I and BamH I (Table 2.6). The 
digests were run on a 1% agarose gel stained with ethidium bromide and the gels were 
photographed using the Chemilmager 4400 Low Light Imaging System. Samples 
appearing to contain the bPL insert (based on apparent molecular weight) were sent to the 
University of Maine DNA Sequencing Facility for sequencing and sequences were 
analyzed using MegaBLAST provided by NCBI. 
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Culture of the Mouse L929 Cells 
Mouse L929 cells (ATCC) were obtained from Dr. Charles Moody and were 
maintained in Medium 1640 (Sigma) supplemented with 10% calf serum and 1% 
glutamine-penicillin- streptomycin (Sigma) in 25cm2 cell culture flasks. In order to pass 
the cells, the media was removed and the cells were washed with enough Dulbecco's 
Phosphate Buffered Saline (DPBS from Sigma) to completely cover the monolayer. The 
cells were then incubated in trypsin-EDTA (Sigma) for one minute until they began to 
round up. The trypsin-EDTA was then removed and the culture vessel was struck against 
the palm in order to dislodge the remaining adherent cells. The cells were then 
resuspended in 5mL complete media and counted using a hemocytometer. Cells were 
seeded in a new 25cm flask at 5x 104 cells/mL with a final volume of 5mL complete 
media per flask. The flasks were kept in a 37°C incubator at 6% CO2 until they were 
confluent and needed to be passed again. 
Optimization of Transfection 
Mouse L929 cells were transfected with the pEGFP-N3 vector (Clontech) (Figure 2.5) 
in order to determine the optimal transfection reagent, Tfx-20 or Tfx-50 (Promega), and 
concentration of DNA to use with the cells. The day before the transfection was to take 
place, two 24-well plates were seeded with 5xl04 cells/well in ImL complete media. The 
plates were kept at 37°C and 6% C02 for 24 hours. Various amounts of purified vector 
DNA (0.25, 0.50, 0.75, and 1.00 ng per well) were tested at two different charge ratios of 
Tfx Reagent:DNA (2:1 and 4:1). One plate was used for transfection with Tfx-20 and the 
other for transfection with Tfx-50. The transfections were set up as shown in Table 2.11, 
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• 
Human cytomegalovirus immediate 
early promoter: bases 1-589 
SV40 origin of replication: bases 
2441-2576 
• 
Multiple cloning site: bases 
591-665 
ISV40 early promoter 
Enhanced green fluorescent 
protein gene: bases 668-1369 
Kanamycin/neomycin resistance 
gene 
SV40 early mRNA 
polyadenylation signal 
Herpes simplex virus/thymidine 
kinase polyadenylation signal 
fl single-strand DNA origin: 
bases 1645-2100 
pUC plasmid replication 
origin: bases 4004-4647 
I Bacterial promoter for expression of Kanr gene 
Figure 2.5. Map of the pEGFP-N3 vector. This map is based on the map provided by 
Clontech. 
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making up an adequate amount of mixture for 3.5 replicates of each DNA concentration 
To begin, the incomplete media (media without calf serum or antibiotics) and plasmid 
DNA were combined in sterile tubes and the tubes were vortexed. The transfection 
reagents were then added and the tubes were vortexed again. The Tfx Reagent/DNA 
mixtures were incubated for 15 minutes at room temperature. The complete media was 
removed from the cells and 200ul of the appropriate mixture was added per well. The 
layout of the 24-well plates is shown in Figure 2.6. The plates were incubated for one 
hour, followed by the addition of 1 mL complete media to each well. The plates were 
returned to the 37°C incubator (6% C02) for 48 hours. After the incubation period was 
complete, the wells were viewed under a fluorescent microscope. 
Table 2.11. Optimization of transfection. 
2:1 charge ratio Amount of pEGFP-N3 per well 
0.25ug 0.50ng 0.75ug 1.00|qg 
Incomplete medium 695.6ul 691.lul 686.8|j.l 682.2ul 
pEGFP-N3 1.8fa.l 3.7u1 5.4ul 7.3ul 
Tfx Reagent 2 ^ 1 52uJ 7 ^ 1 10.5ul 
4:1 charge ratio Amount of pEGFP-N3 per well 
0.25ug 0.50ug 0.75ug 1 .OOug 
Incomplete medium 693.0ul 685.9ul 679.0ul 671.7ul 
pEGFP-N3 1.8ul 3.7ul 5.4ul 7.3ul 
Tfx Reagent 52uJ 10.4ul 15.6ul 21 .Qui 
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Figure 2.6. Plate layout for the optimization of transfection study. Various amounts of 
purified pEGFP-N3 DNA (0.25, 0.50, 0.75, and 1.00 ug per well) were tested at two 
different charge ratios of Tfx Reagent:DNA (2:1 and 4:1). Two plates were set up in this 
manner, one for Tfx-20 and the other for Tfx-50. 
Transfection of the L929 Cells with Purified pcDNA3.1-bPL DNA 
From the optimization of transfection study, it was concluded that the most favorable 
results occurred with the Tfx-20 Reagent at a 2:1 charge ratio and 1.00ug DNA per well. 
It was therefore decided that this was the combination that would be used in the 
transfection of the mouse cells with the pcDNA3.1-bPL recombinant DNA. Twenty-four 
hours before the transfection was to take place, a 24-well plate was seeded with L929 
cells at 5x 104 cells/well in lmL of complete media. The transfection was carried out as 
had been done for the optimization study, this time using 1.00ug pcDNA3.1 -bPL and a 
charge ratio of 2:1 for every well. The media from the cells was collected and replaced 
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with new media every 48 hours for ten days. The collected media was tested for the 
presence of bPL using radioimmunoassay (Wallace, 1993). 
In a second trial, twelve wells of a 24-well plate were transfected with lug 
pcDNA3.1-bPL per well with a charge ratio of 2:1 Tfx-20 Reagent: DNA. The 
remaining twelve wells were to act as the control, being monitored over the course of the 
study for growth. At 12, 24, and 48 hours post-transfection, the media was collected 
from three of the transfected wells and the cells were removed from the surface of the 
flask (using trypsin-EDTA) and were counted. In addition to performing a total cell 
count, the cells were stained with trypan blue in order to distinguish the number of dead 
cells. At each collection point, the cells from three of the control wells were removed 
and counted, once again staining with trypan blue. 
Transfection of a New Batch of Mouse L929 Cells 
A new batch of L929 cells was purchased from American Type Culture Collection. 
The cells were thawed and cultured according to the manufacture's directions. These 
new cells were transfected with pcDNA3.1-bPL. Media was removed from the cells 48 
hours after the transfection reaction took place. The media was then assayed for the 
presence of bPL (Wallace, 1993). 
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Chapter 3 
RESULTS 
Production of the Recombinant bPL Molecule 
bPL cDNA was isolated from the placental tissue of a Holstein dairy cow at day 90 of 
gestation. The bPL gene was identified with the help of primers (bPL-F and bPL-R) that 
were designed using a known bPL sequence reported by Yamakawa el al. (1990). PCR 
techniques were then carried out in order to amplify the DNA fragment of interest. This 
fragment, beginning and ending with the primers, would be composed of 847 nucleotides. 
The fragment was cloned into the pTarget mammalian expression vector and the 
recombinant molecule was transformed into competent JM109 E. coli cells. The 
transformants were plated on LB/Amp/IPTG/X-gal plates, which allowed for blue-white 
color screening of the clones (Table 3.1). 
Table 3.1. Colonies resulting from the transformation of the recombinant pTarget-
bPL molecule into competent JM109 E. coli cells. 
Plate # white colonies # blue colonies Total # colonies 
la 2 4 6 
lb 4 4 8 
2a 15 16 31 
2b 17 15 32 
3a 8 4 12 
3b 7 I 14 
Each of the three ligation reactions involving the pTarget vector and the bPL insert were 
used in the transformation of the recombinant molecule into competent JM109 E. coli 
cells. Two plates were made from each reaction. 
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Two white colonies from each of the six plates were chosen for culture. The DNA 
from the eleven colonies that grew was purified and the purified DNA was then digested 
with the restriction enzymes BamH I and Kpn I. The digests were run on agarose (1 %) 
gel electrophoresis (Figure 3.1). 
...__ 850 bp 
650 bp 
3b2 3bl 3a2 3al 2bl 2a2 2al 1b2 Ibl la2 lal 
Figure 3.1. Gel electrophoresis of the pTarget-bPL restriction digests. Eleven clones 
were digested with Kpn I and BamH I and the digests, along with a lkb plus ladder 
(GibcoBRL) were run on a 1% agarose gel stained with ethidium bromide. All eleven 
clones appeared to contain the bPL insert (band at 800bp). 
Each of the clones appeared to contain the bPL insert and all were sequenced by the 
University of Maine DNA Sequencing Facility. The returned sequences (Figure 3.2) 
were analyzed using the Mega BLAST program. Mega BLAST was able to align the 
plus strands of our sequences with the minus strands of bPL sequences in the GenBank 
database. This told us that our inserts were ligated into the pTarget vector in the incorrect 
orientation (Figure 3.3). In order for proper transcription of the bPL gene to take place, it 
was necessary to have the initiation codon (ATG) of the gene on the plus strand 
following the transcriptional start site of the vector. In the pTarget-bPL recombinant 
molecule, the ATG was on the minus strand. 
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In order to rectify this, it was necessary to remove the bPL insert from the pTarget 
vector and ligate it into another vector, the pcDNA3.1(+) vector. Two of the clones, 
pTarget-bPL-lb2 and pTarget-bPL-3al, were chosen at random to digest. The new 
vector was digested in such a manner that the insert had no choice but to ligate into the 
vector in the correct orientation (Figure 3.4). The pTarget vector came from the 
manufacturer already digested. This vector had been prepared by making a blunt cut and 
adding thymine (T) overhangs, so that each end was identical. For this reason, the insert 
was able to ligate into the vector in both the correct and incorrect orientations. The 
pcDNA3.1(+) vector was preferable to the pTarget vector because we were able to digest 
it ourselves with the enzymes appropriate for our research. In our case, we needed to 
digest with BamH I and Kpn I so that the bPL insert would be ligated in the correct 
orientation. 
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1 cacccaaacatgcattaaagagctataaaactcaaagaagcttttgacgggatggatcat 60 
61 cactaaccatctcaggactggttgggttaattgtgggcttagcatggggtgaatcggcac 120 
121 ttaagcaaattgatgtaggtgctaattttactcgaatccctgtgtaggcagtggaacatt 180 
181 etataaaaggcagt ttggcgcacatcctcatcgtctgctgtcagggaggacttttctgac 240 
241 cacactggatagggctcgttcttcttctctccaggatgaacccttttttgtatcatttcc 300 
301 acaccttctagaagtactttggtcttgtcctcaatctctttagcccttgccaagatatca 360 
361 ggtgaggctccattcctgtgcaacaactctgtgactgcctgatgcagaggttcatcccac 420 
421 gagtggagcaaactgataaccaacctcaatagggcttcgtcaaatteattgaacatttec 480 
481 ctggcgagcctatagttgttgctagccaccaatgttgctctctcaaacaggctttgaagg 540 
541 ggaatccggcagttgccaggttggtttttacagvatggtgcataatcctccacaccctgg 600 
601 cacaagagtagat t tgacaccaccagcagcaggagcaggcaggaccctcgaacaaggtca 660 
661 caaatccactggtgcccacgatggctagatgctggagccatgaggattggagagaaatcc 720 
721 caggatgaggactgctgctgatggggagatggccccaaccagggactgaatggaggaatc 780 
781 tttcccggggggtaccgtcgactgtggccgcgaattc 817 
Figure 3.2. pTarget-bPL sequence. This sequence is 817 base pairs in length and 
aligns with the minus strand of bPL sequences in the GenBank database. 
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The bPL insert was ligated into the pcDNA3.1(+) vector using ligation reaction 1 
(Table 2.5). The recombinant molecules were then transformed into competent E. coli 
cells. Two plates were made from each reaction. 
The five clones (Table 3.2) that resulted were cultured, and the DNA was purified and 
digested with BamH I and Kpn I. The digests were run on gel electrophoresis (Figure 
3.5). 
HAVE WANT 
Figure 3.3. Possible scenarios of the ligation of the bPL insert with the pTarget vector. 
The ATG of the bPL insert is on the minus strand of the recombinant molecule. In order 
for proper transcription of the bPL gene to take place, it is necessary for the ATG of the 
gene to be on the plus strand following the transcriptional start site of the vector. 
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Figure 3.4. Ligating the bPL insert into the vector in the correct orientation, a) restriction 
digest of pTarget-bPL to remove the bPL insert, b) restriction digest of the pcDNA3.1 (+) 
vector to prepare for ligation with the bPL insert, c) ligation of the bPL insert with the 
pcDNA3.1(+) vector to form the recombinant pcDNA3.1-bPL molecule. The insert has 
no choice but to ligate into the vector in the correct orientation. 
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Table 3.2. Colonies resulting from the transformation of the recombinant 
pcDNA3.1-bPL molecule into competent JM109 E. coli cells. 
Plate # white colonies  
lb2-l 1 
lb2-2 0 
3al-l 2 
3al-2 2 
I 1 _ 800 bp 700 bp 
Figure 3.5. Gel electrophoresis of the pcDNA3.1-bPL restriction digests. Five clones 
were cultured and purified. The DNA was then digested with Kpn I and BamH I and the 
digests were run, along with a lOObp ladder (GibcoBRL) on a 1% agarose gel stained 
with ethidium bromide. Four of the five clones contain the bPL insert. 
Four of the five clones appeared to contain the bPL insert and were sent to the 
University of Maine DNA Sequencing Facility for sequencing. The returned sequences 
(Figure 2.4) were analyzed using the Mega BLAST program. As expected. Mega 
BLAST was able to align the plus strands of our sequences with the plus strands of bPL 
sequences in the GenBank database. 
In order for other studies to be performed using the recombinant pcDNA3.1 -bPL 
recombinant molecule (vaccine production, etc.), it was necessary for the bPL gene to be 
in-frame with the transcriptional start site of the pcDNA3.1(+) vector. As can be seen in 
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Figure 3.6, the bPL insert was not in-frame with the transcriptional start site. Also, in 
order for proper initiation to occur, it was necessary to have a G or A at position -3 and a 
G at position +4. Our bPL gene had the G at position +4, but had a C at position - 3 . 
Primers bPL-Start-Kpnl and bPL-Stop-BamHI were designed so as to remedy these 
problems. As can be seen in Figure 3.7, the bPL insert was now in-frame with the 
transcriptional start site of the pcDNA3.1(+) vector and there was a G at position -3 . 
transcriptional start site 
TAG AGA ACC CAC TGC TTA CTG GCT TAT CGA AAT TAA TAC 
GAC TCA CTA TAG GGA GAC CCA AGC TGG CTA GCG TTT AAA 
CTT AAG CTT GGT ACC CCC GGG AAA GAT TCC TCC ATT CAG 
K p n l 
TCC CTG TTG GGC CAT CTC CCC ATC AGC AGC AGT CCT CAT 
CCT GGG ATT TCT CTC CAA TCC TCA TGG 
-3 +4 
Figure 3.6. ATG of pcDNA3.1-bPL is not in-frame with the transcriptional start site. 
The start codon (ATG) of the bPL gene is not in-frame with the transcriptional start site 
of the pcDNA3.1(+) vector. In order for proper initiation of translation to occur, there 
must be an A or G at position -3 and a G at position +4. In this sequence, there was a C 
at position - 3 . The Kpn I recognition site is outlined for reference. 
transcriptional start site 
TAG AGA ACC CAC TGC TTA CTG GCT TAT CGA AAT TAA TAC 
GAC TCA CTA TAG GGA GAC CCA AGC TGG CTA GCG TTT AAA 
CTT AAG CTT GGT ACC GCT ATG GCT 
-3 +4 Kpn I 
Figure 3.7. ATG of pcDNA3.1-bPL is in-frame with the transcriptional start site. The 
start codon (ATG) of the bPL gene was in-frame with the transcriptional start site of the 
pcDNA3.1(+) vector. The requirements for proper initiation have been met, with 
guanines at positions -3 and +4. 
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Description of the bPL Gene 
The bPL cDNA isolated in this study (Figure 3.8) encoded an open reading frame 
from the beginning of the clone to the termination codon (TAA) at nucleotide positions 
670-672. The sequence shown here includes a small number of nucleotides belonging to 
the vector sequence, including the Kpn I and BamH I recognition sites. There was a 
single ATG at nucleotide positions 10-12, which was thought to be the initiating 
methionine. This predicts a preprohormone of 200 amino acids. 
Mega BLAST was able to align the plus strand of our bPL sequence with the plus 
strand of a bPL sequence reported by Schuler et al. (1988), which predicted a 
preprohormone of 236 amino acids. The comparison of the two preprohormone 
sequences is given in Figure 3.9. Schuler et al. (1988) were able to divide their bPL 
sequence into five exons. When aligned with the Schuler sequence, it is evident that the 
bPL sequence of this study was missing the entire third exon. Schuler and her colleagues 
(1988) were also able to identify the first exon as the signal peptide, with the site of 
cleavage following the glycine at amino acid 36. Their mature hormone would therefore 
be 200 amino acids in length. In comparison, our mature protein would be 164 amino 
acids. 
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1 ggtaccgctatggctccagcatctagccatcgtgggcaccagtggatttgtgaccttgtt bu 
Kpn I 
61 cgagggtcctgcctgctcctgctgctggtggtgtcaaatctactcttgtgccagggtgtg 120 
121 gaggattatgcaccatactgtaaaaaccaacctggcaactgccggattccccttcaaagc 180 
181 ctgtttgagagagcaacattggtggctagcaacaactataggctcgccagggaaatgttc 240 
241 aatgaatttgacgaagccctattgaggttggttatcagtttgctccactcgtgggatgaa 300 
301 cctctgcatcaggcagtcacagcgttgttgcacaggaatggagcctcacctgatatcttg 360 
361 gcaagggctaaagagattgaggacaagaccaaagtacttctagaaggtgtggaaatgata 420 
421 caaaaaagggttcatcctggagagaagaagaacgagccctatccagtgtggtcagaaaag 480 
481 tcctccctgacagcagacgatgaggatgtgcgccaaactgccttttatagaatgttccac 540 
541 tgcctacacagggattcgagtaaaattagcacctacatcaatttgcttaagtgccgattc 600 
eui accccatgctaaggatccactagtccagtgtggtggaattc b4i 
BamH I 
Figure 3.8. pcDNA3.1-bPL sequence. The start codon (ATG) and stop codon (TAA) 
are underlined. The Kpn I and BamH I recognition sites are underlined twice for 
reference. 
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Figure 3.9. Comparison of two bPL preprohormone sequences. The sequence given 
is that reported by Schuler et al (1988), along with the corresponding amino acid 
sequence. This sequence was made up of five exons, divided by the vertical lines. The 
dots represent nucleotides of the pcDNA3.1-bPL sequence that match the Schuler 
sequence, while the equal signs represent the missing third exon of pcDNA3.1-bPL. 
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The results of the optimization of transfection study are shown in Figures 3.10 and 
3.11. As can be seen, the L929 cells that were transfected with a 2:1 charge ration of 
Tfx-20:DNA and 1 .OOug pEGFP-N3 per well produced the most favorable results. As 
can be seen in Figure 3.10, a greater number of cells transfected with this combination 
could be visualized under the fluorescent microscope. This results from a greater 
transfection efficiency. For this reason, this combination of charge ration and 
concentration of DNA was used in the transfection of the cells with the pcDNA3.1-bPL. 
The L929 cells were transfected with a 2:1 charge ratio of Tfx-20:DNA and 1 .OOug 
pcDNA3.1 -bPL per well. The media from the cells was collected and replaced with new 
media every 48 hours for ten days. Using radioimmunoassay (Wallace, 1993), it was 
determined that there was an average of 1 .OOng bPL per milliliter of collected media. It 
had been hypothesized that the cells would be able to produce at least 1 OOng bPL per 
milliliter media (unpublished results using mouse L cells). It was noted throughout the 
collection of the media that the L929 cells were not growing at the expected rate. In 
order to determine the reason for this, another transfection of the cells with the 
pcDNA3.1-bPL was carried out, this time also maintaining nontransfected control wells. 
Media collection began 12 hours post-transfection, followed by collection at 24 and 48 
hours post-transfection. At the time of media collection, the cells were trypsinized and 
stained with trypan blue in order to distinguish between the live and dead cells. The 
results of this study are shown in Table 3.3 and Figure 3.12. 
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Figure 3.10. Optimization of transfection with Tfx-20. The combination of the 2:1 charge ratio and l.OOug DNA/well produced the 
highest transfection efficiency. 
Figure 3.11. Optimization of transfection with Tfx-50. The combination of the 2:1 charge ratio and 0.50ug DNA/well produced the 
highest transfection efficiency. 
Table 3.3. Post-transfection cell viability results 
Hours post-
transfection 
Live cells 
(cells/mL) 
Dead cells 
(cells/mL) 
Total cells 
(cells/mL) 
564,000 
724,000 
1,936,000 
464,000 
396,000 
580,000 
Cell viability 
(% cell/mL) 
12 
24 
48 
12 
24 
48 
564,000 
724,000 
1,928,000 
456,000 
388,000 
576,000 
Control wells 
0 
0 
8,000 
Transfected wells 
8,000 
8,000 
4,000 
100 
100 
99.59 
98.28 
97.98 
99.31 
At the indicated times, the cells from three wells of each of the groups (control and 
transfected) were trypsinized. The cells were pooled according to group, stained with 
trypan blue, and counted. 
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Figure 3.12. Growth rate of transfected and non-transfected L929 cells. The total 
number of cells per milliliter of media 12 to 48 hours post-transfection. 
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The cell viabilities of both the control and the transfected wells were comparable. The 
lowest cell viability noted in the control wells was 99.59% at 48 hours post-transfection 
and the lowest in the transfected wells was 97.98% at 24 hours post-transfection. Despite 
the similar cell viabilities, it is clear from Figure 3.12 that the cells of the nontransfected 
control wells were growing at a faster rate than the cells of the transfected wells. By 48 
hours post-transfection, the number of control cells exceeded the number of transfected 
cells by 1,356,000 cells/mL. This seemed to point to the conclusion that the transfection 
was somehow altering the growth rate of the mouse cells. 
Due to the slow growth rate of the L929 cells and the low transfection efficiency, it 
was believed that the cells were carrying a mycoplasma infection. Therefore, a new 
batch of L929 cells was purchased from American Type Culture Collection and the cells 
were transfected with pcDNA3.1-bPL. Media was collected 48 hours post-transfection 
and was assayed for the presence of bPL (Wallace, 1993). The radioimmunoassay was 
unable to detect any bPL in the media. However, at 48 hours post-transfection, the cells 
appeared healthy and had grown to confluency. 
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Chapter 4 
DISCUSSION 
Recombinant DNA technology has enabled advances in a myriad of research interests. 
Proteins that would have, at one time, been difficult to study, are now being produced in 
laboratories all over the world. Bovine placental lactogen, a hormone whose peak 
concentrations are reported at a mere 2.93ng/mL (Wallace, 1993), is no exception. The 
production of recombinant bPL (rbPL) has allowed researchers to delve into the structure 
and function of this mysterious protein, and many discoveries have been made. Site-
directed mutagenesis of rbPL has made it possible to pinpoint exact locations on the 
protein that are important in receptor binding (Vashdi-Elberg et al, 1996; Helman et al, 
1997). The N-terminal portion of bPL, which is not present in growth hormone, has been 
identified as being important in PRL receptor binding (Gertler et al, 1992). bPL has also 
been labeled as a key factor in the regulation of mammary growth and differentiation 
(Byatt et al, 1994; Byatt et al, 1997) and in the stimulation of body weight gain (Byatt et 
al, 1991). In addition, rbPL has been used to study the effects of the hormone on the 
growth and function of heifer ovaries (Lucy et al, 1994). 
Despite these developments, there is one possible downfall to the work that has been 
done with rbPL thus far. The rbPL used in the aforementioned studies was produced in 
bacteria, an expression system that may not be capable of carrying out all of the post-
translational modifications that are important to the function of the protein. 
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In this study, we were able to isolate bPL cDNA from the placental tissue of a 
Holstein dairy cow at day 90 of gestation. We cloned the cDNA into the pcDNA3.1(+) 
vector and transformed the recombinant DNA into E. coli cells. The bPL sequence 
isolated in this study was similar to that isolated by Schuler el al. (1988). The Schuler 
sequence predicted a preprohormone of 236 amino acids and could be divided into five 
exons. Our sequence, however, predicted a preprohormone of only 200 amino acids. 
Upon further analysis of our sequence, it was evident that it was missing the entire third 
exon, as was the sequence isolated by Kessler and Schuler (1991). Kessler and Schuler 
noted that the third exon contains one of the six cysteine residues important to the 
conformation of the mature bPL protein. Although no further research has been reported 
on that particular variant, it was predicted that the missing third exon may change the 
folding pattern of the protein, thus rendering it inactive (Kessler and Schuler, 1991). 
The initial transfection of the recombinant bPL molecule produced much lower yields 
of the protein than expected (as measured by radioimmunoassay (Wallace, 1993)). It was 
noted during the collection of data that the transfected cells were not achieving 
confluence at the typical rate. Two hypotheses were established in order to try to explain 
the poor results: 1) the cells were experiencing some toxicity, caused either by the 
transfection agent or by the bPL and 2) the cells were not dividing properly. It was 
assumed that toxicity would result in low cell viability counts, whereas slow growth and 
division would result in low total cell counts, with high viability. The latter was the 
result that was observed. In the second transfection trial, when compared to the control 
group, the transfected cells were significantly less in number, but still maintained a high 
56 
viability level. This seemed to point to the conclusion that there was something slowing 
cell division in the transfected cultures. 
In a similar study, Xia et al (1997) observed decreased transfection efficiency and 
slow growth of apparently healthy COS cells. It was concluded that the results obtained 
were caused by a mycoplasma infection. Mycoplasma are parasitic prokaryotic 
organisms that are resistant to penicillin-type antibiotics (Rottem, 1980). This means that 
they are able to survive in cell cultures with media containing such antibiotics. The 
typical energy source utilized by mycoplasma is arginine. The utilization of arginine is 
mediated by the enzyme arginine deiminase (Sugimura et al, 1992; Sugimura et al, 
1993). Arginine deiminase activity is thought to disrupt normal vesicular trafficking in 
cells, thus disrupting the liposomal-mediated transfection process (Xia el al, 1997). 
Although the L929 cells were not tested for mycoplasma infection, it is assumed that this 
was the cause of the decreased growth rate of the transfected population. A new batch of 
L929 cells tested for the presence of mycoplasma before purchase were able to grow to 
confluence by 48 hours post-transfection. 
Despite the fact that the new cells appeared to be free of mycoplasma, they still were 
unable to produce the bPL. This led us to believe that there was a problem with the bPL 
sequence that we were using in the transfection. As stated in Chapter 2: Methods and 
Materials, in order to prepare the sequence for the production of a vaccine also needed in 
Dr. Wallace's lab, the sequence 5' to the start codon was removed. Liang et al (1999) in 
their study of ovine placental lactogen (oPL), concluded that the 1.1 kb 5'-flanking 
sequence , and most importantly, the proximal 383 bp of the oPL gene 5'-flanking 
sequence, was key to the transactivation of the oPL gene. In contrast to the lengthy 5'-
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flanking sequence of oPL, the bPL gene 5'-flanking sequence reported by Schuler et al. 
(1988) was 78 bp. Wallis (1993) noted a rapid rate of molecular evolution of ruminant 
placental lactogens. According to comparisons of the amino acid sequences for ovine 
and bovine PLs (Calosi et al, 1989; Schuler et al, 1988), these two hormones differ in 
about 30% of all residues. The structural differences between the ruminant PLs deem it 
difficult to draw conclusions about bPL by making comparisons to oPL. For this reason, 
the next step in the quest for the successful transfection and production of bPL should be 
to fashion a bPL study after the oPL study done by Liang et al (1999). Such a study 
would enable us to see if the 5'-flanking sequence of the bPL gene is required for the 
production of the bPL protein, and if so, which particular region(s) are of the most 
importance. 
Ideally, a full-length bPL sequence should be isolated and cloned. The transfection of 
the full-length sequence, and thus production of the full-length protein, would enable 
comparisons to be made between the it and the proteins resulting from the alternatively 
spliced genes. Overall, the production of bPL in the laboratory through the use of 
transfection will enable researchers to further explore the importance of the different 
structures and functions of this protein. 
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